vedolizumab,ustekinumab,risankizumab
takeda,boehringer ingelheim,abbvie,janssen
[' vedo', 'risan', 'ustekinumab', 'vedolizumab']
 absolute risk of cancer is low even with anti-tnf and this needs to be weighed against the benefits of avoiding steroids, hospitalizations and surgery. having said that there are biologics with no increased risk of cancer incl ustekinumab, vedolizumab and risankizumab
I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.